152 related articles for article (PubMed ID: 2765278)
1. Diagnostic value of monoclonal antibody B72.3 in detecting adenocarcinoma cells in serous effusions.
Lauritzen AF
APMIS; 1989 Aug; 97(8):761-6. PubMed ID: 2765278
[TBL] [Abstract][Full Text] [Related]
2. Distinction between cells in serous effusions using a panel of antibodies.
Lauritzen AF
Virchows Arch A Pathol Anat Histopathol; 1987; 411(3):299-304. PubMed ID: 2441518
[TBL] [Abstract][Full Text] [Related]
3. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions.
Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J
Cancer Res; 1985 Apr; 45(4):1894-900. PubMed ID: 3884146
[TBL] [Abstract][Full Text] [Related]
4. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
5. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
Afify A; Zhou H; Howell L; Paulino AF
Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
[TBL] [Abstract][Full Text] [Related]
8. Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3.
Martin SE; Moshiri S; Thor A; Vilasi V; Chu EW; Schlom J
Am J Clin Pathol; 1986 Jul; 86(1):10-8. PubMed ID: 3524191
[TBL] [Abstract][Full Text] [Related]
9. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
10. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
Chhieng DC; Yee H; Schaefer D; Cangiarella JF; Jagirdar J; Chiriboga LA; Jagirdar J; Chiriboga LA; Cohen JM
Cancer; 2000 Jun; 90(3):194-200. PubMed ID: 10896333
[TBL] [Abstract][Full Text] [Related]
11. Markers for metastatic adenocarcinoma in serous effusion specimens.
Shield PW; Callan JJ; Devine PL
Diagn Cytopathol; 1994; 11(3):237-45. PubMed ID: 7532566
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies in the cytodiagnosis of serous effusions.
al-Nafussi A; Carder PJ
Cytopathology; 1990; 1(2):119-28. PubMed ID: 1714782
[TBL] [Abstract][Full Text] [Related]
13. [Differential diagnostic value of B72.3, Ber-EP4 and calretinin in serous effusions].
Li XJ; Pan QJ; Shen GH; Liu XY; Sun YT
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):438-41. PubMed ID: 16188134
[TBL] [Abstract][Full Text] [Related]
14. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
Delahaye M; van der Ham F; van der Kwast TH
Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
[TBL] [Abstract][Full Text] [Related]
15. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
[TBL] [Abstract][Full Text] [Related]
16. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4.
De Angelis M; Buley ID; Heryet A; Gray W
Cytopathology; 1992; 3(2):111-7. PubMed ID: 1617160
[TBL] [Abstract][Full Text] [Related]
17. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry.
Queiroz C; Barral-Netto M; Bacchi CE
Acta Cytol; 2001; 45(1):18-22. PubMed ID: 11213499
[TBL] [Abstract][Full Text] [Related]
18. Assessment of immunocytochemical and histochemical stainings in the distinction between reactive mesothelial cells and adenocarcinoma cells in body effusions.
Chen CJ; Chang SC; Tseng HH
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Sep; 54(3):149-55. PubMed ID: 7954054
[TBL] [Abstract][Full Text] [Related]
19. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
20. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
Ko EC; Jhala NC; Shultz JJ; Chhieng DC
Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
